Abstract
Research has recently focused on combinational therapy using nanocarriers to overcome the obstacles associated with conventional therapy of lung cancer. The classical therapeutic approach is indeed insufficient for suppressing tumor growth. Simultaneous delivery improves therapeutic outcomes, synergistic effects, and targeting moiety. Besides, multidrug-loaded nanocarriers allows the consecutive release of two or more drugs and genes. A such nanodrug delivery system reduces drug–drug interactions and improves the pharmacokinetics profile of loaded drugs. Currently, nanotechnology-based co-delivery system is the only suitable option for lung cancer therapy. Combinational delivery systems show promising results for the treatment of lung cancer. Here we review the design and development of co-delivery systems based on nanocarriers for effective cancer treatment.
This is a preview of subscription content, log in via an institution to check access.
Reproduced from Au et al. (2015), with permission from American Chemical Society
Reproduced from Taratula et al. (2013), with permission from Elsevier
Similar content being viewed by others
References
Alibolandi M, Ramezani M, Abnous K, Sadeghi F, Atyabi F, Asouri M, Hadizadeh F (2015) In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer. J Controll Release 209:88–100. https://doi.org/10.1016/j.jconrel.2015.04.026
Alibolandi M, Ramezani M, Abnous K, Hadizadeh F (2016) Aptamer-decorated biodegradable polyethylene glycol-poly(lactic-co-glycolic acid) nanopolymersomes for the targeted delivery of gemcitabine to non-small cell lung cancer in vitro. J Pharm Sci 105:1741–1750. https://doi.org/10.1016/j.xphs.2016.02.021
Al-Qattan MN, Deb PK, Tekade R (2018) KMolecular dynamics simulation strategies for designing carbon-nanotube-based targeted drug delivery. Drug Discov Today 23:235–250. https://doi.org/10.1016/j.drudis.2017.10.002
Amreddy N, Babu A, Panneerselvam J, Srivastava A, Muralidharan R, Chen A, Ramesh R (2018) Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomed Nanotechnol Biol Med 14:373–384. https://doi.org/10.1016/j.nano.2017.11.010
Au KM, Min Y, Tian X, Zhang L, Perello V, Caster JM, Wang AZ (2015) Improving cancer chemoradiotherapy treatment by dual controlled release of wortmannin and docetaxel in polymeric nanoparticles. ACS Nano 9:8976–8996. https://doi.org/10.1021/acsnano.5b02913
Babu A, Templeton AK, Munshi A, Ramesh R (2013) Nanoparticle-based drug delivery for therapy of lung cancer: progress and challenges. J Nanomater. https://doi.org/10.1155/2013/863951
Bhattacharjee A (2013) Solid lipid nanoparticles technology as a novel platform for delivery of drugs. Indo Am J Pharm Res 3:4079–4097. https://doi.org/10.1044/1980-iajpr.06832
Castillo RR, Colilla M, Vallet-Regí M (2017) Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer. Expert Opin Drug Deliv 14:229–243. https://doi.org/10.1080/17425247.2016.1211637
Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF (2002) Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 238:241–245. https://doi.org/10.1016/S0378-5173(02)00080-7
Croissant JG, Zhang D, Alsaiari S, Lu J, Deng L, Tamanoi F, Khashab NM (2016) Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in vivo tumor imaging. J Controll Release 229:183–191. https://doi.org/10.1016/j.jconrel.2016.03.030
Das S, Chaudhury A (2011) Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 12:62–76. https://doi.org/10.1208/s12249-010-9563-0
Davis ME, Chen Z, Shin DM (2010) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nanosci Technol Collect Rev Nat J 7:771–782. https://doi.org/10.1142/9789814287005_0025
De Melo-Diogo D, Gaspar VM, Costa EC, Moreira AF, Oppolzer D, Gallardo E, Correia IJ (2014) Combinatorial delivery of Crizotinib–Palbociclib–Sildenafil using TPGS–PLA micelles for improved cancer treatment. Eur J Pharm Biopharm 88:718–729. https://doi.org/10.1016/j.ejpb.2014.09.013
Dilnawaz F, Sahoo SK (2018) Augmented anticancer efficacy by si-RNA complexed drug-loaded mesoporous silica nanoparticles in lung cancer therapy. ACS Appl Nano Mater 1:730–740. https://doi.org/10.1021/acsanm.7b00196
Ding Qu YM, Sun W, Chen Y, Zhou J, Liu C, Huang M (2015) Microemulsion-based synergistic dual-drug codelivery system for enhanced apoptosis of tumor cells. Int J Nanomed 10:1173
Elgohary MM, Helmy MW, Mortada SM, Elzoghby AO (2018) Dual-targeted nano-in-nano albumin carriers enhance the efficacy of combined chemo/herbal therapy of lung cancer. Nanomedicine 13:2221–2224. https://doi.org/10.2217/nnm-2018-0097
Feng T, Tian H, Xu C, Lin L, Xie Z, Lam MHW, Chen X (2014) Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment. Eur J Pharm Biopharm 88:1086–1093. https://doi.org/10.1016/j.ejpb.2014.09.012
Ganesh S, Iyer AK, Gattacceca F, Morrissey DV, Amiji MM (2013) In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J Controll Release 172:699–706. https://doi.org/10.1016/j.jconrel.2013.10.016
Gao H (2016) Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B 6:268–286. https://doi.org/10.1016/j.apsb.2016.05.013
Garbuzenko OB, Winkler J, Tomassone MS, Minko T (2014) Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs. Langmuir 30:12941–12949. https://doi.org/10.1021/la502144z
Han Y, Zhang P, Chen Y, Sun J, Kong F (2014) Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy. Int J Mol Med 34:191–196. https://doi.org/10.3892/ijmm.2014.1770
Han W, Shi L, Ren L, Zhou L, Li T, Qiao Y, Wang H (2018) A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer. Signal Transduct Target Therapy. https://doi.org/10.1038/s41392-018-0019-4
Hao S, Yan Y, Ren X, Xu Y, Chen L, Zhang H (2015) Candesartan-graft-polyethyleneimine cationic micelles for effective co-delivery of drug and gene in anti-angiogenic lung cancer therapy. Biotechnol Bioprocess Eng 20:550–560. https://doi.org/10.1007/s12257-014-0858-y
He Z, Huang J, Xu Y, Zhang X, Teng Y, Huang C, Sun W (2015) Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG–PLGA copolymer nanoparticles for the treatment of non-small lung cancer. Oncotarget 6:42–50. https://doi.org/10.18632/oncotarget.6243
He Y, Su Z, Xue L, Xu H, Zhang C (2016a) Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy. J Controll Release 229:80–92. https://doi.org/10.1016/j.jconrel.2016.03.001
He Z, Shi Z, Sun W, Ma J, Xia J, Zhang X, Huang J (2016b) Hemocompatibility of folic-acid-conjugated amphiphilic PEG–PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer. Tumor Biol 37:7809–7821. https://doi.org/10.1007/s13277-015-4634
Hu CMJ, Zhang L (2012) Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochemical Pharmacol 83(8):1104–1111. https://doi.org/10.1016/j.bcp.2012.01.008
Hu CM, Aryal S, Zhang L (2010) Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 1:323–334. https://doi.org/10.4155/tde.10.13
Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 1:297
Jabbari S, Ghamkhari A, Javadzadeh Y, Salehi R, Davaran S (2018) Doxorubicin and chrysin combination chemotherapy with novel pH-responsive poly[(lactide-co-glycolic acid)-block-methacrylic acid] nanoparticle. J Drug Deliv Sci Technol 46:129–137. https://doi.org/10.1016/j.jddst.2018.05.006
Jaracz S, Chen J, Kuznetsova LV, Ojima I (2005) Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 13:5043–5054. https://doi.org/10.1016/j.bmc.2005.04.084
Jeannot V, Gauche C, Mazzaferro S, Couvet M, Vanwonterghem L, Henry M, Schatz C (2018) Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer. J Controll Release 275:117–128. https://doi.org/10.1016/j.jconrel.2018.02.024
Jiang K, Shen M, Xu W (2018) Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation. Int J Nanomed 13:25–61. https://doi.org/10.2147/IJN.S157746
Kabary DM, Helmy MW, Elkhodairy KA, Fang JY, Elzoghby AO (2018) Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of rapamycin and berberine to lung carcinoma. Colloids Surf B 169:183–194. https://doi.org/10.1016/j.colsurfb.2018.05.008
Li Q, Lv S, Tang Z, Liu M, Zhang D, Yang Y, Chen X (2014) A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation. Int J Pharm 471:412–420. https://doi.org/10.1016/j.ijpharm.2014.05.065
Li C, Hu J, Li W, Song G, Shen J (2017a) Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment. Biomater Sci 5:77–88. https://doi.org/10.1039/C6BM00449K
Li F, Mei H, Gao Y, Xie X, Nie H, Li T, Jia L (2017b) Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer. Biomaterials 145:56–71. https://doi.org/10.1016/j.biomaterials.2017.08.030
Li S, Wang L, Li N, Liu Y, Su H (2017c) Combination lung cancer chemotherapy: design of a pH-sensitive transferrin-PEG-Hz-lipid conjugate for the co-delivery of docetaxel and baicalin. Biomed Pharmacother 95:548–555. https://doi.org/10.1016/j.biopha.2017.08.090
Li Z, Tan S, Li S, Shen Q, Wang K (2017d) Cancer drug delivery in the nano era: an overview and perspectives. Oncol Rep 38:611–624. https://doi.org/10.3892/or.2017.5718
Liu J, He J, Zhang M, Xu G, Ni PA (2018) synergistic polyphosphoester-based co-delivery system of the anticancer drug doxorubicin and the tumor suppressor gene p53 for lung cancer therapy. J Mater Chem B 6:3262–3273. https://doi.org/10.1039/C8TB00746B
Lv S, Tang Z, Li M, Lin J, Song W, Liu H, Huang Y, Zhang Y, Chen X (2014) Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials 35:6118–6129. https://doi.org/10.1016/j.biomaterials.2014.04.034
Mahajan S, Patharkar A, Kuche K, Maheshwari R, Deb PK, Kalia K, Tekade RK (2018) Functionalized carbon nanotubes as emerging delivery system for the treatment of cancer. Int J Pharm. https://doi.org/10.1016/j.ijpharm.2018.07.027
Mandal B et al (2013) Core–shell-type lipid–polymer hybrid nanoparticles as a drug delivery platform. Nanomed Nanotechnol Biol Med 9:474–491. https://doi.org/10.1016/j.nano.2012.11.010
Marguet M, Edembe L, Lecommandoux S (2012) Polymersomes in polymersomes: multiple loading and permeability control. Angew Chem 124(5):1199–1202. https://doi.org/10.1002/anie.201106410
Martínez-Carmona M, Colilla M, Vallet-Regí M (2015) Smart mesoporous nanomaterials for antitumor therapy. Nanomaterials 5:1906–1937. https://doi.org/10.3390/nano5041906
Melani AS (2007) Inhalatory therapy training: a priority challenge for the physician. Acta Biomed 78:233–245
Mi Y, Mu C, Wolfram J, Deng Z, Hu TY, Liu X, Ferrari MA (2016) micro/nano composite for combination treatment of melanoma lung metastasis. Adv Healthc Mater 5:936–946. https://doi.org/10.1002/adhm.201500910
Mohammad IS, He W, Yin LA (2018) smart paclitaxel-disulfiram nanocrystals for efficient MDR reversal and enhanced apoptosis. Pharm Res 35:77. https://doi.org/10.1007/s11095-018-2370-0
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Nonsmall cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584–594. https://doi.org/10.4065/83.5.584
Muddineti OS, Shah A, Rompicharla SVK, Ghosh B, Biswas S (2018) Cholesterol-grafted chitosan micelles as a nanocarrier system for drug-siRNA co-delivery to the lung cancer cells. Int J Biol Macromol 118:857–863. https://doi.org/10.1016/j.ijbiomac.2018.06.114
Olov N, Bagheri-Khoulenjani S, Mirzadeh H (2018) Combinational drug delivery using nanocarriers for breast cancer treatments: a review. J Biomed Mater Res Part A 106:2272–2283. https://doi.org/10.1002/jbm.a.36410
Otto DP, Otto A, de Villiers MM (2015) Differences in physicochemical properties to consider in the design, evaluation and choice between microparticles and nanoparticles for drug delivery. Expert Opin Drug Deliv 12:763–777. https://doi.org/10.1517/17425247.2015.988135
Parashar P, Rathor M, Dwivedi M, Saraf SA (2018) Hyaluronic acid decorated naringenin nanoparticles: appraisal of chemopreventive and curative potential for lung cancer. Pharmaceutics 10:33. https://doi.org/10.3390/pharmaceutics10010033
Pushpalatha R, Selvamuthukumar S, Kilimozhi D (2017) Nanocarrier mediated combination drug delivery for chemotherapy: a review. J Drug Deliv Sci Technol 39:362–371. https://doi.org/10.1016/j.jddst.2017.04.019
Qu MH, Zeng RF, Fang S, Dai QS, Li HP, Long JT (2014) Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Int J Pharm 474:112–122. https://doi.org/10.1016/j.ijpharm.2014.08.019
Rabinow BE (2004) Nanosuspensions in drug delivery. Nat Rev Drug Discov 3:785–796. https://doi.org/10.1038/nrd1494
Ramalingam SS, Owonikoko TK, Khuri FR (2011) Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 61(2):91–112. https://doi.org/10.3322/caac.20102
Sahoo SK, Labhasetwar V (2003) Nanotech approaches to drug delivery and imaging. Drug Discov Today 8:1112–1120. https://doi.org/10.1016/S1359-6446(03)02903-9
Seifi-Najmi M, Hajivalili M, Safaralizadeh R, Sadreddini S, Esmaeili S, Razavi R, Ahmadi M (2016) SiRNA/DOX lodeded chitosan-based nanoparticles: development, characterization and in vitro evaluation on A549 lung cancer cell line. Cell Mol Biol (Noisy-le-grand) 62:87–94
Shao Z, Shao J, Tan B, Guan S, Liu Z, Zhao Z, Zhao J (2015) Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int J Nanomed 10:1223
Shen J, Yin Q, Chen L, Zhang Z, Li Y (2012) Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 33:8613–8624. https://doi.org/10.1016/j.biomaterials.2012.08.007
Singh RP, Sharma G, Singh S, Kumar M, Pandey BL, Koch B, Muthu MS (2016) Vitamin E TPGS conjugated carbon nanotubes improved efficacy of docetaxel with safety for lung cancer treatment. Colloids Surf B 141:429–442. https://doi.org/10.1016/j.colsurfb.2016.02.011
Song W, Tang Z, Li M, Lv S, Sun H, Deng M, Chen X (2014) Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects. Acta Biomater 10:1392–1402. https://doi.org/10.1016/j.actbio.2013.11.026
Su WP, Cheng FY, Shieh DB, Yeh CS, Su WC (2012) PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomed 7:4269
Su C-W, Chiang C-S, Li W-M, Hu S-H, Chen S-Y (2014) Multifunctional nanocarriers for simultaneous encapsulation of hydrophobic and hydrophilic drugs in cancer treatment. Nanomedicine. https://doi.org/10.2217/nnm.14.97
Sung JC, Pulliam BL, Edwards DA (2007) Nanoparticles for drug delivery to the lungs. Trends Biotechnol 25:563–570. https://doi.org/10.1016/j.tibtech.2007.09.005
Taratula O, Garbuzenko OB, Chen AM, Minko T (2011) Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target 19:900–914. https://doi.org/10.3109/1061186X.2011.622404
Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T (2013) Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Controll Release 171:349–357. https://doi.org/10.1016/j.jconrel.2013.04.018
Tian J, Min Y, Rodgers Z, Au KM, Hagan CT, Zhang M, Wang AZ (2017a) Co-delivery of paclitaxel and cisplatin with biocompatible PLGA–PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models. J Mater Chem B 5:6049–6057. https://doi.org/10.1039/C7TB01370A
Tian J, Min Y, Rodgers Z, Wan X, Qiu H, Mi Y, Roche K (2017b) Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer. Nanomed Nanotechnol Biol Med 13:1301–1307. https://doi.org/10.1016/j.nano.2016.11.007
Wakaskar RR (2018) General overview of lipid–polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes. J Drug Target 26:311–318. https://doi.org/10.1080/1061186X.2017.1367006
Wan X, Min Y, Bludau H, Keith A, Sheiko SS, Jordan R, Kabanov AV (2018) Drug combination synergy in worm-like polymeric micelles improves treatment outcome for small cell and non-small cell lung cancer. ACS Nano 12:2426–2439. https://doi.org/10.1021/acsnano.7b07878
Wang BL, Shen YM, Zhang QW, Li YL, Luo M, Liu Z, Shi HS (2013) Codelivery of curcumin and doxorubicin by MPEG–PCL results in improved efficacy of systemically administered chemotherapy in mice with lung cancer. Int J Nanomed 8:3521. https://doi.org/10.2147/IJN.S45250
Wang Y, Zhang H, Hao J, Li B, Li M, Xiuwen W (2016) Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect. Drug Deliv 23:1398–1403. https://doi.org/10.3109/10717544.2015.1055619
Wang G, Wang Z, Li C, Duan G, Wang K, Li Q, Tao T (2018a) RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy. Biomed Pharmacother 106:275–284. https://doi.org/10.1016/j.biopha.2018.06.137
Wang XS, Zhang L, Li X, Kong DJ, Hu XC, Ding XZ, Gao SG (2018b) Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo. Nanomedicine 10:1107–1120. https://doi.org/10.2217/nnm-2017-0355
Wei W, Lv PP, Chen XM, Yue ZG, Fu Q, Liu SY, Ma GH (2013) Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. Biomaterials 34:3912–3923. https://doi.org/10.1016/j.biomaterials.2013.02.030
Wu D, Wang C, Yang J, Wang H, Han H, Zhang A, Li Q (2016) Improving the intracellular drug concentration in lung cancer treatment through the codelivery of doxorubicin and miR-519c mediated by porous PLGA microparticle. Mol Pharm 13:3925–3933. https://doi.org/10.1021/acs.molpharmaceut.6b00702
Xiong Y, Zhao Y, Miao L, Lin CM, Huang L (2016) Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. J Controll Release 244:63–73. https://doi.org/10.1016/j.jconrel.2016.11.005
Xu W, Ling P, Zhang T (2013) Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly watersoluble drugs. J Drug Deliv 13:340–415. https://doi.org/10.1155/2013/340315
Yokoyama M (2011) Clinical applications of polymeric micelle carrier systems in chemotherapy and image diagnosis of solid tumors. Int J Clin Exp Med 3:151–158. https://doi.org/10.1016/j.jecm.2011.06.002
Youlden DR, Cramb SM, Baade PD (2008) The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 3:819–831. https://doi.org/10.1097/JTO.0b013e31818020eb
Yu H, Xu Z, Chen X, Xu L, Yin Q, Zhang Z, Li Y (2014) Reversal of lung cancer multidrug resistance by p H-R esponsive micelleplexes mediating Co-D elivery of si RNA and paclitaxel. Macromol Biosci 14:100–109. https://doi.org/10.1002/mabi.201300282
Zhang L et al (2008) Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2:1696–1702. https://doi.org/10.1021/nn800275r
Zhang W, Li C, Shen C, Liu Y, Zhao X, Liu Y, Yue C (2016a) Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment. Drug Deliv 23:2575–2580. https://doi.org/10.3109/10717544.2015.1035466
Zhang X, Wang Q, Qin L, Fu H, Fang Y, Han B, Duan Y (2016b) EGF-modified mPEG–PLGA–PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer. Drug Deliv 23:2936–2945. https://doi.org/10.3109/10717544.2015.1126769
Zhu L, Perche F, Wang T, Torchilin VP (2014) Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. Biomaterials. https://doi.org/10.1016/j.biomaterials.2014.01.060
Zylberberg C, Matosevic S (2016) Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Deliv 23:3319–3329. https://doi.org/10.1080/10717544.2016.1177136
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Farooq, M.A., Aquib, M., Khan, D.H. et al. Nanocarrier-mediated co-delivery systems for lung cancer therapy: recent developments and prospects. Environ Chem Lett 17, 1565–1583 (2019). https://doi.org/10.1007/s10311-019-00897-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10311-019-00897-7